<div id="readability-page-1"><p>In a report released yesterday, Derek Archila from Wells Fargo maintained a Buy rating on Kymera Therapeutics, with a price target of <span id="expert-recommendation-target">$116.00</span>.</p><h3>Claim 50% Off TipRanks Premium and Invest with Confidence </h3><ul><li>Unlock  hedge-fund level data  and  powerful investing tools  designed to help you make smarter, sharper decisions  </li><li> Stay ahead of the market with  the latest news and analysis  so your portfolio is always positioned for maximum potential</li></ul> <p>According to TipRanks, Archila is a 5-star analyst with an average return of <span>19.1%</span> and a 54.56% success rate. Archila covers the Healthcare sector, focusing on stocks such as Kyverna Therapeutics, Inc., Incyte, and Argenx Se.</p> <p>In addition to Wells Fargo, Kymera Therapeutics also received a Buy from RBC Capital’s Maurice Choy in a report issued yesterday. However, on December 11, TR | OpenAI – 4o reiterated a Hold rating on Kymera Therapeutics (NASDAQ: KYMR).</p></div>

KYMR

<p>Wells Fargo analyst Derek Archila maintains a Buy rating on Kymera Therapeutics with a $116 price target. Archila, a 5-star analyst, has a 19.1% average return and a 54.56% success rate. RBC Capital also issued a Buy rating, while TR reiterated a Hold rating on December 11.</p>

Kymera Therapeutics (KYMR) Gets a Buy from Wells Fargo